Beta Bionics, Inc.
BBNX
$19.09
-$0.40-2.05%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -13.70% | 22.36% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -13.70% | 22.36% | |||
| Cost of Revenue | -0.95% | 12.32% | |||
| Gross Profit | -23.25% | 31.13% | |||
| SG&A Expenses | 29.08% | 5.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.38% | 20.93% | |||
| Operating Income | -42.99% | -18.77% | |||
| Income Before Tax | -58.25% | -85.99% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -58.25% | -85.99% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -58.25% | -85.99% | |||
| EBIT | -42.99% | -18.77% | |||
| EBITDA | -43.22% | -20.00% | |||
| EPS Basic | 65.66% | -74.79% | |||
| Normalized Basic EPS | 65.66% | -74.79% | |||
| EPS Diluted | 65.66% | -74.79% | |||
| Normalized Diluted EPS | 65.66% | -74.79% | |||
| Average Basic Shares Outstanding | 360.80% | 6.41% | |||
| Average Diluted Shares Outstanding | 360.80% | 6.41% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||